NanoSmart moves to new HQ and begins work on Ab-based delivery tech

- Last updated on GMT

Privately-owned US biotech NanoSmart Pharmaceuticals says it has started work on a delivery platform for cancer drugs after moving into a new corporate HQ.

NanoSmart, which is now based at Laguna Hills, California this week, is working on a human autoimmune antibody-based technology that, the firm claims, offers improved tumour targeting capabilities by focusing on areas of necrosis, dead tissue, found in many types of cancer.

CEO Henry Smith said that the new facility’s laboratory and administrative space allow the firm to to begin formal development of its initial product pipeline.

"Our new location gives us a physical presence in Orange County, California and allows us to move forward with our strategic development goals. We are excited about the opportunity to develop our initial products and conduct formal, nonclinical studies leading towards our initial regulatory filings​.”

Related topics: Bio Developments

Related news

Follow us

Products

View more

Webinars